drugset

drugset / Trial / NCT00582985

Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

NCT00582985 ↗

Phase 1 Completed 51 enrolled Tracon Pharmaceuticals Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.

Timeline

Start: 2007-12
Primary completion: 2011-06
Completion: 2011-06

Publications

Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y. Endoglin-targeted cancer therapy. Curr Drug Deliv. 2011 Jan;8(1):135-43. doi: 10.2174/156720111793663570.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carotuximab	Monoclonal antibody	—	Intravenous

Indications